Clazakizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Clazakizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 2/3
Highest phase
26
Registered trials
19
Result records
4
Matched deals
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Clazakizumab can convert its Monoclonal antibody profile and IL-6 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Clazakizumab (query alias: clazakizumab) |
|---|---|
| Modality / target | Monoclonal antibody; IL-6; IL-6 inhibitors |
| Highest global status | Phase 2/3 |
| Originator | Lundbeck Seattle BioPharmaceuticals, Inc. |
| Active developers | CSL Behring LLC |
The MCP disease footprint includes Myocardial Infarction, Atherosclerosis, Kidney Failure, Chronic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05485961 | Phase 2/3 | Recruiting | 3110 | Change from Baseline on the log scale in high-sensitivity C-reactive protein (hs-CRP)(Phase 2b) |
| NCT05727384 | Phase 2 | Completed | 29 | Mean Change in Speed of Walking 400 Meters from Baseline to 24 Weeks |
| ACTRN12624000567527 | Phase 2 | Not yet recruiting | 10 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Phase 3; n=194; evaluation: not stated. Reported fields: Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)(Least Squares Mean) = -5.2 milliliter per minute per 1.73 meter^2 (95% Confidence Interval, -7.4 to -3.1); Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)(Least Squares Mean) = -8.0 milliliter per minute per 1.73 meter^2 (95% Confidence Interval, -10.2 to -5.8); Change From Baseline to Week 52 in Estimated Glomerular Filtration Rate (eGFR)(Least Squares Mean): Treatment difference = -2.75(95% CI, -5.84 to 0.35)
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
Phase 1/2; n=10; evaluation: not stated. Reported fields: -; -; Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing = 7 Participants
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: CRP = 90 mg l^-1 ; CRP = 86 mg l^-1 ; CRP = 92 mg l^-1
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Clazakizumab addresses Myocardial Infarction, Atherosclerosis, Kidney Failure, Chronic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-02-18 | Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study | Phase 2/3 | Financial terms not disclosed |
| 2017-12-05 | CSL Behring to Acquire Biotech Company Vitaeris | Phase 2 | US$15.0M upfront |
| 2016-05-06 | Alder Licenses Clazakizumab Rights to Newly Formed Vitaeris | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Composition and stable liquid formulations comprising humanized Anti-human interleukin 6 (il-6) receptor monoclonal antibodies”. The milestone feed surfaced a patent-application signal described as “Treatments for conditions involving increased il-6 levels”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
